Status:
COMPLETED
Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device
Lead Sponsor:
Oulu University Hospital
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or doc...
Eligibility Criteria
Inclusion
- Signed informed consent
- Planned initiation of oxaliplatin-, vincristine- or docetaxel-containing chemotherapy regimen \[FOLFOX, XELOX, (R)-CHOP/CHOEP/CVOP, docetaxel, docetaxel-doxorubicin\]
- Age \>18y
- ECOG 0-2
- Patient compliant with the study procedures
Exclusion
- Patient not fit/suitable for aforementioned chemotherapy regimen at baseline
- Any prior postoperative or post-traumatic conditions affecting the sensory and/or motoric peripheral nerves
- General vulnerability affecting the participation in the trial
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04778878
Start Date
October 1 2019
End Date
February 28 2021
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oulu University Hospital
Oulu, Finland